Blog

Roche pays $775M upfront for Cambridge biotech’s sophomore cancer drug

jeff-albersheadshot1900xx3500-2333-0-2

A Cambridge biotech is rebounding from an FDA rejection by signing a deal with drug giant Roche worth upwards of $1.7 billion.

Read More